 |
13 Diseases |  |
0 Trials |
|
0 Trials |  |
47 News |  |
- RPh201 / Regenera
Epidemic of Subclinical Ovulatory Disturbances During SARS-COV2 Pandemic—an Experiment of Nature (In Person in Atlanta B404) - Jul 16, 2022 - Abstract #ENDO2022ENDO_876;
In MOS, ovulation was assessed by 3-fold increased follicular (FP)-to-luteal (LP/premenstrual) urinary progesterone (PdG); in MOS2, by validated Quantitative Basal Temperatur
- || RPh201 / Regenera
Clinical, P1 data, Journal: A First-in-Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers. (Pubmed Central) - May 29, 2021
No deaths or adverse events related to changes in vital signs or electrocardiograms were reported. No occurrences of suicidal behavior or ideation were reported.
- ||||| RPh201 / Regenera
Trial completion date, Trial termination, Trial primary completion date: Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Oct 12, 2020
P2, N=165, Terminated, Sponsor: Regenera Pharma Ltd
No occurrences of suicidal behavior or ideation were reported. Trial completion date: Aug 2021 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Apr 2021 --> Sep 2020; Terminated by Sponsor
- | RPh201 / Regenera
Preclinical, Journal: Delayed (21 Days) Post Stroke Treatment With RPh201, a Botany-Derived Compound, Improves Neurological Functional Recovery in a Rat Model of Embolic Stroke. (Pubmed Central) - Aug 28, 2020
Our data demonstrated that RPh201 has a therapeutic effect on improvement of functional recovery in male ischemic rats even when the treatment was initiated 21 days post stroke. Enhanced axonal and myelination densities by RPh201 in ischemic brain may contribute to improved stroke recovery.
- | QPI-1007 / Quark, RPh201 / Regenera
Review, Journal: Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy. (Pubmed Central) - Jul 19, 2020
Enhanced axonal and myelination densities by RPh201 in ischemic brain may contribute to improved stroke recovery. Unfortunately, in spite of all the experimental and clinical research on neuroprotection agents in NA-AION so far, we have no scientifically proven evidence of neuroprotection agents showing any benefit in the human clinical studies so far.
- ||| RPh201 / Regenera
Enrollment open, Phase classification, Trial completion date, Trial primary completion date: Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Jul 7, 2020
P2, N=200, Recruiting, Sponsor: Regenera Pharma Ltd
Unfortunately, in spite of all the experimental and clinical research on neuroprotection agents in NA-AION so far, we have no scientifically proven evidence of neuroprotection agents showing any benefit in the human clinical studies so far. Active, not recruiting --> Recruiting | Phase classification: P3 --> P2 | Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Nov 2020 --> Apr 2021
- || RPh201 / Regenera
Clinical, P2a data, Journal: Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy. (Pubmed Central) - Jun 18, 2020
P2
No safety concerns were raised. The results support a larger trial in patients with previous NAION.
- ||| RPh201 / Regenera
Trial completion, Trial completion date: A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease (clinicaltrials.gov) - Apr 30, 2020
P2, N=83, Completed, Sponsor: Regenera Pharma Ltd
The results support a larger trial in patients with previous NAION. Recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2020
- ||||| RPh201 / Regenera
Enrollment closed: Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Mar 24, 2020
P3, N=234, Active, not recruiting, Sponsor: Regenera Pharma Ltd
Recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2020 Recruiting --> Active, not recruiting
- RPh201 / Regenera
Delayed (21 Days) Post Stroke Treatment With RPh201, A Botany-Derived Compound, Improves Neurological Functional Recovery in a Rat Model of Embolic Stroke (Hall H) - Dec 21, 2019 - Abstract #ISC2020ISC_1873;
Our data demonstrated that RPh201 has a therapeutic effect on improvement of functional recovery in male ischemic rats even when the treatment was initiated 21 days post stroke. Enhanced axonal and myelination densities by RPh201 in ischemic brain may contribute to improved stroke recovery.
- |||| RPh201 / Regenera
Trial completion date, Trial primary completion date: Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Dec 17, 2019
P3, N=234, Recruiting, Sponsor: Regenera Pharma Ltd
Enhanced axonal and myelination densities by RPh201 in ischemic brain may contribute to improved stroke recovery. Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Nov 2020
- || RPh201 / Regenera
Trial completion date, Trial primary completion date: A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease (clinicaltrials.gov) - Jun 14, 2019
P2, N=81, Recruiting, Sponsor: Regenera Pharma Ltd
Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Nov 2020 Trial completion date: Apr 2019 --> Jul 2020 | Trial primary completion date: Feb 2019 --> Dec 2019
- | RPh201 / Regenera
Enrollment change: Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds (clinicaltrials.gov) - Sep 4, 2018
P1/2, N=4, Terminated, Sponsor: Regenera Pharma Ltd
Trial completion date: Apr 2019 --> Jul 2020 | Trial primary completion date: Feb 2019 --> Dec 2019 N=15 --> 4
- | RPh201 / Regenera
New P2 trial: A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease (clinicaltrials.gov) - Jul 27, 2018
P2, N=81, Recruiting, Sponsor: Regenera Pharma Ltd
- | RPh201 / Regenera
Enrollment open: Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Jul 27, 2018
P3, N=234, Recruiting, Sponsor: Regenera Pharma Ltd
N=15 --> 4 Not yet recruiting --> Recruiting
- |||||||||| RPh201 / Regenera
New P3 trial: Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Jun 6, 2018
P3, N=234, Not yet recruiting, Sponsor: Regenera Pharma Ltd
- ||||| RPh201 / Regenera
New P2 trial: A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease (clinicaltrials.gov) - Mar 12, 2018
P2, N=80, Recruiting, Sponsor: Regenera Pharma Ltd
- | RPh201 / Regenera
Trial completion date, Trial suspension, Trial primary completion date: The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (clinicaltrials.gov) - Feb 6, 2018
P1, N=10, Suspended, Sponsor: Hadassah Medical Organization
Not yet recruiting --> Recruiting Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> Jan 2019 | Trial completion date: Oct 2018 --> Oct 2020
- RPh201 / Regenera
Trial initiation date, Trial primary completion date: Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn (clinicaltrials.gov) - Dec 6, 2016
P1/2, N=0, Withdrawn, Sponsor: Regenera Pharma Ltd
Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> Jan 2019 | Trial completion date: Oct 2018 --> Oct 2020 Initiation date: Dec 2014 --> Dec 2011 | Trial primary completion date: Dec 2015 --> Dec 2011
- | RPh201 / Regenera
Trial completion, Trial primary completion date: Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). (clinicaltrials.gov) - Dec 6, 2016
P2, N=23, Completed, Sponsor: Regenera Pharma Ltd
Initiation date: Dec 2014 --> Dec 2011 | Trial primary completion date: Dec 2015 --> Dec 2011 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2016
- | RPh201 / Regenera
Trial completion, Enrollment change: A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease (clinicaltrials.gov) - Dec 6, 2016
P1/2, N=36, Completed, Sponsor: Regenera Pharma Ltd
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2016 Recruiting --> Completed | N=56 --> 36
- RPh201 / Regenera
Trial primary completion date: The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (clinicaltrials.gov) - Sep 24, 2015
P1, N=10, Recruiting, Sponsor: Hadassah Medical Organization
Recruiting --> Completed | N=56 --> 36 Trial primary completion date: Jan 2014 --> Jan 2017
- RPh201 / Regenera
Enrollment change, Trial withdrawal, Trial primary completion date: The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements (clinicaltrials.gov) - Sep 23, 2015
P1/2, N=0, Withdrawn, Sponsor: Hadassah Medical Organization
Trial primary completion date: Jan 2014 --> Jan 2017 N=10 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2013 --> Oct 2017
- || RPh201 / Regenera
Trial primary completion date: A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease (clinicaltrials.gov) - Dec 25, 2014
P1/2, N=56, Recruiting, Sponsor: Regenera Pharma Ltd
N=10 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2013 --> Oct 2017 Trial primary completion date: Dec 2013 --> Jun 2015
- | RPh201 / Regenera
Enrollment open: Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). (clinicaltrials.gov) - Apr 26, 2014
P2, N=20, Recruiting, Sponsor: Regenera Pharma Ltd
Trial primary completion date: Dec 2013 --> Jun 2015 Not yet recruiting --> Recruiting
- RPh201 / Regenera
Trial withdrawal: Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn (clinicaltrials.gov) - Jan 22, 2014
P1/2, N=0, Withdrawn, Sponsor: Regenera Pharma Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- RPh201 / Regenera
Trial initiation date: Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn (clinicaltrials.gov) - Jan 22, 2014
P1/2, N=0, Withdrawn, Sponsor: Regenera Pharma Ltd
Not yet recruiting --> Withdrawn Initiation date: Dec 2011 --> Dec 2014
- RPh201 / Regenera
Enrollment change: Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn (clinicaltrials.gov) - Jan 22, 2014
P1/2, N=0, Withdrawn, Sponsor: Regenera Pharma Ltd
Initiation date: Dec 2011 --> Dec 2014 N=20 --> 0
- | RPh201 / Regenera
New P2 trial: Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). (clinicaltrials.gov) - Jan 22, 2014
P2, N=20, Recruiting, Sponsor: Regenera Pharma Ltd
- RPh201 / Regenera
Trial initiation date: The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (clinicaltrials.gov) - Mar 19, 2013
P1, N=10, Recruiting, Sponsor: Hadassah Medical Organization
N=20 --> 0 Initiation date: Oct 2011 --> Sep 2012
- RPh201 / Regenera
Enrollment open: The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (clinicaltrials.gov) - Mar 19, 2013
P1, N=10, Recruiting, Sponsor: Hadassah Medical Organization
Initiation date: Oct 2011 --> Sep 2012 Not yet recruiting --> Recruiting
- RPh201 / Regenera
Trial termination: Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds (clinicaltrials.gov) - Oct 14, 2012
P1/2, N=15, Terminated, Sponsor: Regenera Pharma Ltd
Not yet recruiting --> Recruiting Recruiting --> Terminated; Due to slow recruitment
- ||||| RPh201 / Regenera
New P1/2 trial: A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease (clinicaltrials.gov) - Jan 18, 2012
P1/2, N=56, Recruiting, Sponsor: Regenera Pharma Ltd
- RPh201 / Regenera
New P1/2 trial: Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn (clinicaltrials.gov) - Oct 18, 2011
P1/2, N=0, Withdrawn, Sponsor: Regenera Pharma Ltd
- RPh201 / Regenera
New P1 trial: The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (clinicaltrials.gov) - Sep 20, 2011
P1, N=10, Recruiting, Sponsor: Hadassah Medical Organization
- RPh201 / Regenera
New P1/2 trial: Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds (clinicaltrials.gov) - Sep 5, 2011
P1/2, N=15, Terminated, Sponsor: Regenera Pharma Ltd
- RPh201 / Regenera
New P1/2 trial: The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements (clinicaltrials.gov) - Aug 14, 2011
P1/2, N=10, Not yet recruiting, Sponsor: Hadassah Medical Organization